Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension

References

• Nishikawa K, Naka T, Chatani F, et al. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997;11(Suppl 2):9–17
   PubMed Web of Science ®Google Scholar
• Timmermans PBMWM, Wong CM, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205–51
   PubMed Web of Science ®Google Scholar
• Gradman AH, Arcuri KE, Goldberg AI, et al. A randomised, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25: 1345–50
   PubMed Web of Science ®Google Scholar
• Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonists, irbesartan with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12:203–08
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renine-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387–93
   Google Scholar
• Easthope SE, Jarvis B. Candesartan cilexetil – an update of its use in essential hypertension. Drugs 2002;62(8):1253–87
   PubMed Web of Science ®Google Scholar
• Gleiter CH, Jägle C, Gresser U, et al. Candesartan. Cardiovasc Drug Rev 2004;22(4):263–84
   PubMedGoogle Scholar
• Ross A, Papademetriou V. Candesartan cilexetil in cardiovascular disease. Expert Rev Cardiovasc Ther 2004;2(6):829–35
   PubMedGoogle Scholar
• Meredith PA. ACE inhibition and AT1 receptor blockers: efficacy and duration in hypertension. Heart 2000;84(Suppl 1): i39–i41
   PubMedGoogle Scholar
• Heuer HJ, et al. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(Suppl 2): S55–S56
   PubMedGoogle Scholar
• Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004;20(5):597–602
   Google Scholar
• Fenton C, Scott LJ. Candesartan cilexetil – a review of its use in the management of chronic heart failure. Drugs 2005;65(4): 537–58
   PubMed Web of Science ®Google Scholar
• Mancia G, Dell’Oro R, Turri C, Grassi G. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol 1999;84:28S–34S
   Google Scholar
• Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Pressure 2001;10:43–51
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hypertens 1999;12:1181–7
   PubMed Web of Science ®Google Scholar
• Koenig W, on behalf of the Multicentre Study Group. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study. Clin Drug Invest 2000;19(4):239–46
   Google Scholar
• Asmar R, Lacourcière Y. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. J Hypertens 2000;18:1683–90
   PubMed Web of Science ®Google Scholar
• Huebner R, Hoegemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997;11(Suppl 2):S19–S25
   PubMedGoogle Scholar
• White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998;18:588–99
   PubMed Web of Science ®Google Scholar
• Sever PS. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. J Hum Hypertens 1999;13(Suppl 1):S3–S10
   PubMedGoogle Scholar
• Gradman AH. AT1-receptor blockers: differences that matter. J Hum Hypertens 2002;16:S9–S16
   PubMed Web of Science ®Google Scholar
• Morsing P, Vauquelin G. How can the differences among AT1-receptor antagonists be explained? Cell Biochem Biophys 2001;35:89–102
   PubMed Web of Science ®Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14(Suppl 1):S73–S86
   PubMedGoogle Scholar
• Ojima M, Inada Y, Shibouta Y, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997;319:137–46
   PubMed Web of Science ®Google Scholar
• Timmermans P. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999;15(Suppl F):26F–28F
   Google Scholar
• Delacretaz E, Nussberg J, Biollaz J, et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14–21
   PubMed Web of Science ®Google Scholar
• Mallion JM, Baguet JP. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data. J Hum Hypertens 2000;14(Suppl 2):S33–S41
   PubMedGoogle Scholar
• Noda M, Shibouta Y, Inada Y, et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993;46(2):311–8
   PubMed Web of Science ®Google Scholar
• Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertens 1999;33: 1406–13
   Google Scholar
• Inada Y, Ojima M, Kanagawa R, et al. Pharmacologic properties of candesartan cilexetil – possible mechanisms of long-acting antihypertensive action. J Hum Hypertens 1999;13(Suppl 1): S75–S80
   PubMedGoogle Scholar
• Abrahamsson T, Brandt-Eliasson U, Morsing P, Sjöquist PO. Candesartan causes a long-lasting antagonism of the angiotensin II receptor mediated contractile effects in isolated vascular preparation: a comparison with losartan and its active metabolite (EXP 3174) [abstract]. Am J Hypertension 1998;11(Suppl 2):36A
   Google Scholar
• Belz GG, Fucas B, Malerczyk C, Magin SG, Roll S, Mutschler E. Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers. J Hum Hypertens 1997;11(Suppl 2):S45–S47
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Mancia G, Frattola A, Groppelli A, et al. Blood pressure reduction and end-organ damage in hypertension. J Hypertens 1994;12(Suppl 8):S41–S42
   Google Scholar
• Meredith PA. Organ protection and optimal blood pressure control. Am J Hypertens 1995;8(10 pt 2):59–62S
   Google Scholar
• Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978;1:795–7
   Google Scholar
• Floras JS, Jones JV, Johnston JA, et al. Arousal and the circadian rhythm of blood pressure. Clin Sci Mol Med 1978;4(Suppl):395s–397s
   Google Scholar
• Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987;60:801–6
   PubMed Web of Science ®Google Scholar
• Spielberg C, Falkenhahn D, Willich SN, et al. Circadian, day-of-week, and seasonal variability in myocardial infarction: comparison between working and retired patients. Am Heart J 1996;132:579–85
   PubMed Web of Science ®Google Scholar